Atriva Therapeutics’ lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies,
today announced new results on the efficacy of Atriva’s lead candidate zapnometinib against coronaviruses.

Press Release

Open the
Press Release